Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.

PubWeight™: 1.07‹?› | Rank: Top 10%

🔗 View Article (PMID 11782588)

Published in J Acquir Immune Defic Syndr on January 01, 2002

Authors

Antonio Aceti1, Caterina Pasquazzi, Barbara Zechini, Carlo De Bac, LIVERHAART Group

Author Affiliations

1: Department of Infectious and Tropical Diseases, II Faculty of Medicine, University of Rome La Sapienza, Rome, Italy. professoraceti@tiscalinet.it

Articles citing this

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother (2012) 1.54

Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med (2004) 1.41

HIV, Hepatitis B, and Hepatitis C in Zambia. J Glob Infect Dis (2011) 1.22

Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10

Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01

Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol (2006) 1.00

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis (2005) 0.99

Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS (2009) 0.96

The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95

High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil. Eur J Clin Microbiol Infect Dis (2005) 0.89

Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr (2008) 0.85

Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci (2016) 0.85

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol (2013) 0.84

Association of high viral load and abnormal liver function with high aflatoxin B1-albumin adduct levels in HIV-positive Ghanaians: preliminary observations. Food Addit Contam Part A Chem Anal Control Expo Risk Assess (2011) 0.83

Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis (2008) 0.83

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play? Eur J Med Res (2009) 0.82

Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis (2004) 0.81

Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep (2005) 0.80

Aflatoxin levels, plasma vitamins A and E concentrations, and their association with HIV and hepatitis B virus infections in Ghanaians: a cross-sectional study. J Int AIDS Soc (2011) 0.80

Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. PLoS One (2011) 0.77

Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol (2016) 0.75

Drug-Induced Liver Injury in HIV Patients. Gastroenterol Hepatol (N Y) (2006) 0.75

HIV-HCV Coinfection. Gastroenterol Hepatol (N Y) (2006) 0.75

Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf (2017) 0.75

Articles by these authors

Hymenolepis diminuta infection in a child living in the urban area of Rome, Italy. J Clin Microbiol (2003) 1.29

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology (2006) 1.28

Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol (2004) 1.02

A case report of pityriasis lichenoides in a patient with chronic hepatitis C. J Infect (2005) 0.83

Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy. Liver Int (2005) 0.80

Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C. Clin Immunol (2002) 0.78

Helicobacter pylori active infection in patients with acute coronary heart disease. J Infect (2004) 0.77

Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology (2003) 0.75

Alanine aminotransferase decrease in HIV-hepatitis C virus co-infected patients responding to antiretroviral therapy. AIDS (2003) 0.75

Emergency treatment of a salmonella-infected abdominal aortic aneurysm associated with spondylodiscitis. Ann Ital Chir (2012) 0.75

Development of hepatotoxicity in HIV patients switching at least one protease inhibitor. Int J STD AIDS (2005) 0.75